- Synthesis and electrochemical property of sulfone-functionalized imidazolium ionic liquid electrolytes
-
Sulfone-functionalized imidazolium ionic liquids were synthesized from direct nucleophilic substitution for the first time. Detailed NMR analysis of the products revealed the competition pathways of classic SN2 substitution and E2 elimination i
- Weng, Wei,Zhang, Zhengcheng,Schlueter, John A.,Amine, Khalil
-
-
Read Online
- Compound, liquid crystal composition, liquid crystal display element and liquid crystal display
-
The present invention relates to a compound, a liquid crystal composition, a liquid crystal display element, and a liquid crystal display. The compound is a compound represented by a formula I shown in the description. The liquid crystal composition of the present invention contains the compound represented by the formula I. The compound represented by the formula I has the advantages of good mutual solubility with other compounds and good UV resistance. As a reactive mesogen (RM), the compound has the advantages of good mutual solubility, high polymerization activity (less monomer residue), and strong binding ability. The compound can not only be used as a self-aligning agent for the liquid crystal compositions alone, but also can be used as a vertical alignment material for copolymerization with other RMs so as to be used as a self-aligning agent for the liquid crystal compositions in a PSA (polymer-supported alignment) and PS (polymer-stabilized) mode, the PI preparation process canbe avoided, the preparation process of the liquid crystal display element or liquid crystal display can be simplified, and the production efficiency can be improved.
- -
-
Paragraph 0130; 0141-0143
(2020/02/27)
-
- Compounds, liquid crystal composition, liquid crystal display element and liquid crystal display
-
The invention relates to compounds, a liquid crystal composition, a liquid crystal display element and a liquid crystal display. The compounds are represented by a formula I shown in the description.The liquid crystal composition provided by the invention
- -
-
Paragraph 0148; 0159; 0160; 0161
(2020/02/27)
-
- 2 - (amino) ethyl methyl sulphone salt and wherein the intermediate preparation method
-
The invention discloses a preparation method of a 2-(amino)ethyl methyl sulfone salt represented by formula 1. The preparation method comprises: (1) in an organic solvent and under the action of a substitution reaction catalyst, a compound 3 is reacted with a compound 4; and X is a halogen, and M is an alkali metal or an alkaline earth metal; and (2) a compound 2 prepared by the step (1) is reacted with an acidic aqueous solution to obtain a compound 1; n is equal to 1 or 2; m is equal to 1 or 2; and HmA is an organic acid or an inorganic acid. The invention also discloses a preparation method of the compound 2. The preparation method of the compound 2 comprises: 1) in an organic solvent and under the action of an alkali, a compound 5 is reacted with a halogenation reagent; and 2) in the organic solvent, under the action of the substitution reaction catalyst, the compound 4 is reacted with the compound 3 prepared by the step 1), X is a halogen, and M is an alkali metal or an alkaline earth metal. The preparation methods have low cost and easy availability of raw materials, have no environmental pollution factors, and are suitable for industrial mass production.
- -
-
Paragraph 0055; 0056
(2017/02/28)
-
- ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS
-
The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.
- -
-
Paragraph 0729
(2016/08/10)
-
- HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
- -
-
Paragraph 00393
(2015/02/02)
-